drugset
drugset / Trial / NCT01798485

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

NCT01798485 ↗

Phase 3 Terminated 696 enrolled Synta Pharmaceuticals Corp.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.

Timeline

Start
2013-04
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Ganetespib Small molecule 150 mg/m2 Intravenous

Indications

lung adenocarcinoma